Are you considering taking an updated vaccine? Are you concerned about the risks and potential for autoimmune reactions post-vaccination? You're not alone.

Why timing and avoiding infection is important. (Updated 9/24/2023)

Are you considering taking an updated vaccine? Are you concerned about the risks and potential for autoimmune reactions post-vaccination? You're not alone. Similar concerns have arisen not only with mRNA vaccines but also with other vaccine types and after COVID infections.

Research and observations from trials, such as those for HIV, malaria, and the Pertussis vaccine, have indicated that repeated vaccinations can lead to reduced protection from infection. A consistently overlooked point is on the timing of vaccination after a prior dose and/or after an infection and what could happen if infected in the months after receiving a COVID vaccine. How does the immune system respond? Importantly, is the booster going to provide a benefit and for how long? Lastly, How well will it work against what is looking to be the next dominant variant, BA.2.86 (Pirola)?

“We found that BA.2.86 is antigenically distinct from XBB.1.5 and can escape XBB-induced neutralizing antibodies. The updated vaccine's efficacy against BA.2.86 should be closely monitored.”(1)

The Lim Lab at Arizona State University sequencing picked up BA.2.86 (Pirola) showing up in the last bar on this graph for the week ending Sept 18, 2023 and it is around 15 to 20% of the sequenced cases, from zero the week before. That's means it is spreading fast. BA.2.86.1 with 2 additional mutations is confirmed in 9 states, , including PA, OH, NY, VA, WA, TX, OR, MD and CO while BA.2.86 is in at least 7 states. Pirola is probably much more widespread already. In a U.K. care home, BA.2.86.1 had an 86% Attack Rate!

Pirola evades all available monoclonal antibodies (2) (3). A study published on Sept 7th says, “These results suggest that BA.2.86 is one of the most highly immune evasive variants ever.”(3) A study published on Sept 18, 2023 says, “These findings suggest that BA.2.86 potentially has greater fitness than current circulating XBB variants including EG.5.1."(4) Based on all of this, it has pretty good odds of becoming the next dominant variant.

This update explains the likely reason the autoimmune response is occurring after vaccination or infection, presents a biomarker that can be tested for and importantly it presents a known treatment. It's not just about vaccination; it's about the complete picture. We emphasize the significance of avoiding infections both before and after taking the vaccine. In this comprehensive exploration, we evaluate the feasibility of the XBB 1.5 targeted booster.

The issue of airborne transmission cannot be ignored. It's not just a matter of individual health but also public health. Neglecting airborne transmission contributes to tens of thousands of people daily becoming Long-COVID sufferers. Moreover, it aids the virus's evolution by providing it with an endless supply of hosts, some of whom become long-term homes for COVID.

Let's address these concerns openly and clearly. It's essential for people to understand the risks associated with not taking infection prevention seriously before or after vaccination, as well as the broader risks of repeated infections. Your health and the health of our communities depend on it.

---

Don't miss out on valuable insights! Join our community of informed readers for free today. You will get an email when the paywall comes down, granting you access to the full article.

The research requires extensive time and effort to uncover crucial insights. By becoming a paid subscriber, you're not only gaining access to exclusive content but also actively supporting the future of this important work. Contribute to our mission by becoming a valued paid subscriber today.